Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

2.

Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.

Bononi A, Napolitano A, Pass HI, Yang H, Carbone M.

Expert Rev Respir Med. 2015 Oct;9(5):633-54. doi: 10.1586/17476348.2015.1081066. Epub 2015 Aug 26. Review.

3.

Lung cancer: Biology and treatment options.

Lemjabbar-Alaoui H, Hassan OU, Yang YW, Buchanan P.

Biochim Biophys Acta. 2015 Dec;1856(2):189-210. doi: 10.1016/j.bbcan.2015.08.002. Epub 2015 Aug 19. Review.

4.

Inhibition of mesothelioma cancer stem-like cells with adenovirus-mediated NK4 gene therapy.

Deng XB, Xiao L, Wu Y, Jin F, Mossman B, Testa JR, Xiao GH.

Int J Cancer. 2015 Jul 15;137(2):481-90. doi: 10.1002/ijc.29391. Epub 2014 Dec 27.

5.

Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.

Cheng NC, van Zandwijk N, Reid G.

PLoS One. 2014 Mar 3;9(3):e90374. doi: 10.1371/journal.pone.0090374. eCollection 2014.

6.

Malignant mesothelioma presenting as a gradually enlarging pneumothorax.

Prasad A, Olsen D, Sriram PS.

Case Rep Pulmonol. 2013;2013:374960. doi: 10.1155/2013/374960. Epub 2013 Oct 2.

7.

Arsenic, asbestos and radon: emerging players in lung tumorigenesis.

Hubaux R, Becker-Santos DD, Enfield KS, Lam S, Lam WL, Martinez VD.

Environ Health. 2012 Nov 22;11:89. doi: 10.1186/1476-069X-11-89. Review.

8.

Circumferential pleural shadow.

George J; Jayakrishnan B, Jain R, Al-Rawas OA.

Oman Med J. 2008 Oct;23(4):291-2. No abstract available.

9.

Transforming growth factor-β-induced protein (TGFBI) suppresses mesothelioma progression through the Akt/mTOR pathway.

Wen G, Hong M, Li B, Liao W, Cheng SK, Hu B, Calaf GM, Lu P, Partridge MA, Tong J, Hei TK.

Int J Oncol. 2011 Oct;39(4):1001-9. doi: 10.3892/ijo.2011.1097. Epub 2011 Jun 23.

10.

A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma.

Benjamin H, Lebanony D, Rosenwald S, Cohen L, Gibori H, Barabash N, Ashkenazi K, Goren E, Meiri E, Morgenstern S, Perelman M, Barshack I, Goren Y, Edmonston TB, Chajut A, Aharonov R, Bentwich Z, Rosenfeld N, Cohen D.

J Mol Diagn. 2010 Nov;12(6):771-9. doi: 10.2353/jmoldx.2010.090169. Epub 2010 Sep 23.

11.

Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.

Silberhumer GR, Brader P, Wong J, Serganova IS, Gönen M, Gonzalez SJ, Blasberg R, Zamarin D, Fong Y.

Mol Cancer Ther. 2010 Oct;9(10):2761-9. doi: 10.1158/1535-7163.MCT-10-0090. Epub 2010 Sep 21.

13.

Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects.

Ivanova AV, Ivanov SV, Prudkin L, Nonaka D, Liu Z, Tsao A, Wistuba I, Roth J, Pass HI.

Mol Cancer. 2009 Oct 24;8:91. doi: 10.1186/1476-4598-8-91.

14.

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity.

Stish BJ, Oh S, Chen H, Dudek AZ, Kratzke RA, Vallera DA.

Br J Cancer. 2009 Oct 6;101(7):1114-23. doi: 10.1038/sj.bjc.6605297.

15.

The urokinase receptor supports tumorigenesis of human malignant pleural mesothelioma cells.

Tucker TA, Dean C, Komissarov AA, Koenig K, Mazar AP, Pendurthi U, Allen T, Idell S.

Am J Respir Cell Mol Biol. 2010 Jun;42(6):685-96. doi: 10.1165/rcmb.2008-0433OC. Epub 2009 Jul 27.

16.

Malignant mesothelioma.

Moore AJ, Parker RJ, Wiggins J.

Orphanet J Rare Dis. 2008 Dec 19;3:34. doi: 10.1186/1750-1172-3-34. Review.

Supplemental Content

Support Center